Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of Escitalopram
Authors:
- Lucas C. QuarantiniLQLucas C. Quarantini
- Cristianne R. GóisCGCristianne R. Góis
- Rogério Santos-JesusRSRogério Santos-Jesus
- Ângela M.A. Miranda-ScippaÂMÂngela M.A. Miranda-Scippa
- Irismar R. de OliveiraIOIrismar R. de Oliveira
- Helena da Silva PradoHPHelena da Silva Prado
- James F. LeckmanJLJames F. Leckman
- Maria C. RosárioMRMaria C. Rosário
- 1 July 2007
- journal article
- clinical trial
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 12 (7) , 519-524
Abstract
Introduction: Selective serotonin reuptake inhibitors are considered the most effective and well-established pharmacotherapy for the treatment of obsessive-compulsive disorder (OCD), a chronic and disabling condition. However, ~40% of patients do not have a significant improvement, suggesting that new medications are needed. This study was designed to investigate the treatment response to escitalopram in OCD patients. Methods: This open-label study involved 11 adult OCD outpatients diagnosed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I Disorders. Data were collected and the treatment response was assessed by an experienced psychiatrist by using the Yale-Brown Obsessive-Compulsive Scale. Subjects received escitalopram 30 mg/day for 12 weeks starting at 10 mg/day. Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient. Results: Six of the 11 patients (54.5%) presented a reduction of at least 40% in the baseline total Yale-Brown Obsessive-Compulsive Scale scores. Conclusion: Despite the small sample size and the open-label nature of this trial, these data suggest that escitalopram may be a useful option for patients with OCD.Keywords
This publication has 29 references indexed in Scilit:
- Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week studyCurrent Medical Research and Opinion, 2007
- Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety DisorderThe Journal of Clinical Psychiatry, 2005
- A Preliminary Study of Luteal Phase Versus Symptom-Onset Dosing With Escitalopram for Premenstrual Dysphoric DisorderThe Journal of Clinical Psychiatry, 2005
- Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive DisorderJAMA, 2004
- Citalopram Concentrations and Response in Obsessive-Compulsive DisorderCNS Drugs, 2004
- Escitalopram in the Treatment of Panic DisorderThe Journal of Clinical Psychiatry, 2003
- EscitalopramExpert Opinion on Investigational Drugs, 2002
- Treatment non-response in OCD: methodological issues and operational definitionsInternational Journal of Neuropsychopharmacology, 2002
- Evidence-based pharmacotherapy of obsessive–compulsive disorderInternational Journal of Neuropsychopharmacology, 1999
- The Yale-Brown Obsessive Compulsive ScaleArchives of General Psychiatry, 1989